03 Profile
Hansard to 11 November 2026 · 31,429 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Academic · Cosmetic procedures & aesthetics
Pallavi Oruganti
DVM, CDC Epidemic Intelligence Service (first author of the MMWR report)
press citations on 1 topic since 9 Oct 2026 · last quoted 14 Oct 2026
02 Quoted on · 1 of 29 topics
Pallavi Oruganti: key facts
- Kind of voice
- Academic
- Role
- DVM, CDC Epidemic Intelligence Service (first author of the MMWR report)
- Quoted on
- Cosmetic procedures & aesthetics
- Tracked press citations
- 2
- Most recently quoted
- 14 Oct 2026
- First quoted
- 9 Oct 2026
04 The signal · where Pallavi Oruganti sits on cosmetic procedures & aesthetics
Ranked 37= of 100 voices quoted in the press on cosmetic procedures & aesthetics, level with 42 others on 2 citations.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1
Ashton CollinsSector leaderDirector, Save Face12 - 2
Nora NugentClinicianConsultant Plastic Surgeon and co-owner/Director; Immediate Past President of BAAPS (President 2024–2026), Purity Bridge8 - 3=
Dr Sophie ShotterSector leaderPresident, British College of Aesthetic Medicine (BCAM)6 - 37=Victoria BrownlieSector leaderchief policy and sustainability officer at the British Beauty Council2
- 37=Dr Priyanka ChadhaClinicianplastic surgeon and key opinion leader for Galderma at Amer Clinic2
- 37=Pallavi OrugantiAcademicDVM, CDC Epidemic Intelligence Service (first author of the MMWR report)2
- 37=Doris GrinspunSector leaderCEO of the Registered Nurses Association of Ontario2
- 37=Natia RufoloCliniciannurse practitioner2
Showing the leaders and the ranks around 37=, of 100 voices · See every voice on the topic →
05 On the record · press
What Pallavi Oruganti has said
- medpagetoday.com1
- medscape.com1
Where Pallavi Oruganti has been quoted
- 01CDC Cites Spa for Using Unapproved Botulinum Toxinmedscape.com · 14 Oct 2026
- 02Unapproved Med Spa Botox Tied to Adverse Eventsmedpagetoday.com · 9 Oct 2026
Verbatim
“BoNT purchased from an unauthorized supplier might not be FDA-approved and might be counterfeit, contaminated, improperly stored, or otherwise unsafe. Persons should be encouraged to seek treatment only from licensed providers administering FDA-approved BoNT products. Providers should not purchase or administer unapproved BoNT products from unauthorized sources.”
“inappropriate use of a preservative-containing diluent, use of single-dose vials for multiple patients, inadequate temperature monitoring, and storage and use of reconstituted and unlabeled product past the beyond-use date”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 10 Nov 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.